Conv. Plasma
Nigella Sativa
Nitric Oxide
Peg.. Lambda

Home   COVID-19 treatment studies for Hydroxychloroquine  COVID-19 treatment studies for HCQ  C19 studies: HCQ  HCQ   Select treatmentSelect treatmentTreatmentsTreatments
Alkalinization Meta Lactoferrin Meta
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent:  
0 0.5 1 1.5 2+ Discharge -55% Improvement Relative Risk Viral clearance 10% Babalola et al. PACTR202108891693522 HCQ RCT LATE Is late treatment with HCQ+AZ beneficial for COVID-19? RCT 60 patients in Nigeria Lower discharge with HCQ+AZ (not stat. sig., p=0.2) Babalola et al., J. Infectious Diseases and Epid.., doi:10.23937/2474-3658/1510233 Favors HCQ Favors control
A Randomized Controlled Trial of Ivermectin Monotherapy Versus Hydroxychloroquine, Ivermectin, and Azithromycin Combination Therapy in Covid-19 Patients in Nigeria
Babalola et al., Journal of Infectious Diseases and Epidemiology, doi:10.23937/2474-3658/1510233 (date from earlier preprint), PACTR202108891693522
Babalola et al., A Randomized Controlled Trial of Ivermectin Monotherapy Versus Hydroxychloroquine, Ivermectin, and.., Journal of Infectious Diseases and Epidemiology, doi:10.23937/2474-3658/1510233 (date from earlier preprint), PACTR202108891693522
Oct 2021   Source   PDF  
  All Studies   Meta
Small RCT with 61 patients in Nigeria, all patients treated with ivermectin, zinc, and vitamin C, showing no significant improvements in recovery with the addition of HCQ+AZ.
risk of no hospital discharge, 54.5% higher, RR 1.55, p = 0.20, treatment 17 of 30 (56.7%), control 11 of 30 (36.7%), day 7.
risk of no viral clearance, 9.5% lower, RR 0.90, p = 0.78, treatment 19 of 30 (63.3%), control 21 of 30 (70.0%), NNT 15, day 5 mid-recovery.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Babalola et al., 1 Oct 2021, Single Blind Randomized Controlled Trial, Nigeria, peer-reviewed, 6 authors, this trial uses multiple treatments in the treatment arm (combined with AZ) - results of individual treatments may vary, trial PACTR202108891693522.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperHCQAll
Abstract: 4 ISSN: 2474-3658 Babalola et al. J Infect Dis Epidemiol 2021, 7:233 DOI: 10.23937/2474-3658/1510233 Volume 7 | Issue 10 Open Access Journal of Infectious Diseases and Epidemiology Randomised Drug Trial A Randomized Controlled Trial of Ivermectin Monotherapy versus Hydroxychloroquine, Ivermectin, and Azithromycin Combination Therapy in COVID- 19 Patients in Nigeria Babalola OE1*, Ndanusa YA2, Ajayi AA3, Ogedengbe JO4, Thairu Y4 and Omede O5 Bingham University, Karu, Nigeria Al Ummah Foundation, Abuja, Nigeria 3 Baylor College of Medicine, Texas, USA 4 University of Abuja, Nigeria 5 Federal Ministry of Health, Abuja, Nigeria 1 2 Check for updates *Corresponding author: Olufemi Emmanuel Babalola, Bingham University, Karu, Nigeria Abstract The efficacy of Ivermectin (IVM) against SARS-CoV-2 has been demonstrated in vitro, while several clinical studies suggest that it is efficacious and safe in reducing morbidity and mortality. Hydroxychloroquine (HCQ, Quinoric®), IVM and Azithromycin(AZM, Zithromax®) (HIA therapy) is being used in several low- and middle-income countries (LMIC) where more expensive medications such as Remdesivir are out of reach. In this study, we set out to compare the efficacy of IVM monotherapy with HIA combination therapy. Methods: This was a single-blind, randomized control trial, of 2 parallel groups of COVID-19 Positive Nigerians. Thirty (30) patients received Ivermectin (Mectizan®) 200 mcg/ kg daily for five days, while 31 patients received HIA triple therapy. Viral cycle threshold (Ct) at pre-treatment baseline, and days 2, 5, 14 and 21 were measured for E- and N-genes (Envelope and Nucleocapsid genes respectively). SpO2 (percentage saturation of oxygen in the blood) was assessed on a daily basis, while inflammatory markers such as Erythrocyte Sedimentation Rate (ESR), C-Reactive Protein, and D-dimer and Neutrophil/Lymphocyte Ratios (NLR), were assessed at baseline and day 7 post treatment. Clinical status was self-assessed daily on a Likert scale. Results: 2-way Repeated measures Analysis of Variance (RMANOVA) did not show any difference between the two groups. However, there was a significant time effect (improvement over time) for SpO2, Ct N-gene, Ct E-gene and clinical status in both groups, and significant reductions in inflammatory markers by day 7 (P < 0.0001). Conclusions: AZT + HCQ may be redundant adjuncts in COVID-19 therapy. Improvements noted are likely due in large part to Ivermectin virucidal and anti-inflammatory actions.
Late treatment
is less effective
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop